New regimens and new medications in the treatment of tuberculosis: keeping step?

Y. Ruzanov Dmitry; A.M.  Skriagina; I.V.  Buinevich; S.V.  Goponiako; G.S.  Balasaniantс; E.S.  Khimova

doi:10.36488/cmac.2021.1.27-42

New regimens and new medications in the treatment of tuberculosis: keeping step?

Clinical Microbiology and Antimicrobial Chemotherapy. 2021; 23(1):27-42

Ruzanov D.Y., Skriagina A.M., Buinevich I.V., Goponiako S.V., Balasaniantс G.S., Khimova E.S.

10.36488/cmac.2021.1.27-42

tuberculosis drug resistance treatment regimens bedaquiline delamanid

Section

Diseases and Pathogens

Type

Review

Publication

Clinical Microbiology and Antimicrobial Chemotherapy. 2021; 23(1):27-42

Abstract Authors Literature PDF Statistics

Abstract

Rapid tests detecting Mycobacterium tuberculosis and drug resistance which are universally implemented in medical practice has dramatically improved the diagnosis of rifampicin-resistant tuberculosis and shortened turnaround time thus enabling early etiotropic therapy. However, permanently increasing drug resistance of M. tuberculosis makes treatment less effective. Furthermore, long treatment courses are required due to low sterilizing activity of treatment regimens used for drug-resistant tuberculosis which leads to greater toxic effects, reduces patients’ adherence to treatment and consumes resources of medical care systems. Current phthisiology needs new effective medications and short treatment regimens, otherwise elimination of tuberculosis by 2050 is impossible. This review summarizes the information about treatment of drugresistant TB, including repurposed drugs, new medications and treatment regimens.

Dmitry Y. Ruzanov

druzanoff@mail.ru

Republican Research and Practical Centre for Medical Technologies, Informatization, Healthcare Management and Economics, Minsk, Republic of Belarus

Skriagina A.M.

Republican Research and Practical Centre for Pulmonology and Tuberculosis, Minsk, Republic of Belarus

Buinevich I.V.

Gomel State Medical University, Gomel, Republic of Belarus

Goponiako S.V.

Gomel State Medical University, Gomel, Republic of Belarus

Balasaniantс G.S.

Military Medical Academy named after S.M. Kirov, Saint-Petersburg, Russia

Khimova E.S.

Northern State Medical University, Arkhangelsk, Russia

1. World Health Organization. Global tuberculosis report 2019 (WHO/CDS/TB/2019.15). 2020. Available at: www.who.int/tb/publications/global_report/en/. Accessed January 30, 2021.
2. World Health Organization. Guidelines for the management of drug-resistant tuberculosis (WHO/TB/96.210 Rev.1). 1997. Available at: https://apps.who.int/iris/bitstream/handle/106665/63465/WHO_TB_96.210_(Rev.1).pdf;jsessionid=20AD8869DC687E069E0D25D8267E4025?sequence=1. Accessed January 30, 2021.
3. Hughes J., Isaakidis P., Andries A., Mansoor H., Cox V., Meintjes G., et al. Linezolid for multidrugresistant tuberculosis in HIV-infected and -uninfected patients. Eur Respir J. 2015;46:271-274. DOI: 10.1183/09031936.00188114
4. Lienhardt C., Raviglione M., Spigelman M., Hafner R., Jaramillo E., Hoelscher M., et al. New drugs for the treatment of tuberculosis: needs, challenges, promise, and prospects for the future. J Infect Dis. 2012;205:241-249. DOI: 10.1093/infdis/jis034
5. Tiberi S., Payen M.C., Sotgiu G., D’Ambrosio L., Alarcon Guizado V., Alffenaar J.W., et al. Effectiveness and safety of meropenem/clavulanate-containing regimens in the treatment of MDR- and XDR-TB. Eur Respir J. 2016;47:12351243. DOI: 10.1183/13993003.02146-2015
6. Skripconoka V., Danilovits M., Pehme L., Tomson T., Skenders G., Kummik T., et al. Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis. Eur Respir J. 2013;41:1393-1400. DOI: 10.1183/09031936.00125812
7. Wallis R.S., Maeurer M., Mwaba P., Chakaya J., Rustomjee R., Migliori G.B. Tuberculosis – advances in development of new drugs, treatment regimens, host-directed therapies, and biomarkers. Lancet Infect Dis. 2016;16:3446. DOI: 10.1016/S1473-3099(16)00070-0
8. Tiberi S., Muñoz-TorricoM., Duarte R., Dalcolmo M., D’Ambrosio L., Migliori, G-B. New drugs and perspectives for new anti-tuberculosis regimens. Pulmonology. 2018;24(2):86-98. DOI: 10.1016/j.rppnen.2017.10.009
9. Falzon D., Gandhi N., Migliori G.B., Sotgiu G., Cox H.S., Holtz T.H., et al. Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomes. Eur Respir J. 2013;42:156-168. DOI: 10.1183/09031936.00134712
10. Guglielmetti L., Le Dû D., Veziris N., Caumes E., MarigotOuttandy D., Yazdanpanah Y., et al. Is bedaquiline as effective as fluoroquinolones in the treatment of multidrugresistant tuberculosis? Eur Respir J. 2016;48:582-585. DOI: 10.1183/13993003.00411-2016
11. Gillespie S.H., Crook A.M., McHugh T.D., Mendel C.M., Meredith S.K., Murray S.R., et al. Four month moxifloxacinbased regimens for drug-sensitive tuberculosis. N Engl J Med. 2014;371:1577-1587. DOI: 10.1056/NEJMoa1407426
12. Merle C.S., Fielding K., Sow O.B., Gninafon M., Lo M.B., Mthiyane T., et al. A four-month gatifloxacincontaining regimen for treating tuberculosis. N Engl J Med. 2014;371:1588-1598. DOI: 10.1056/NEJMoa1315817
13. Jawahar M.S., Banurekha V.V., Paramasivan C.N., Rahman F., Ramachandran R., Venkatesan P., et al. Randomized clinical trial of thrice weekly 4-month moxifloxacin or gatifloxacin containing regimens in the treatment of new sputum positive pulmonary tuberculosis patients. PLoS One. 2013;8(7):e67030. DOI: 10.1371/journal.pone.0067030
14. Blasi F., Dara M., van der Werf M.J., Migliori G.B. Supporting TB clinicians managing difficult cases: the ERS/WHO consilium. Eur Respir J. 2013;41:491-494. DOI: 10.1183/09031936.00196712
15. Horsburgh Jr. C.R., Barry C.E. 3rd, Lange C. Treatment of tuberculosis. N Engl J Med. 2015;373:2149-2160. DOI: 10.1056/NEJMra 1413919
16. Ashtekar D.R., Costa-Periera R., Shrinivasan T., Iyyer R., Vishvanathan N., Rittel W. Oxazolidinone, a new class of synthetic antituberculosis agent: in vitro and in vivo activities of DuP-721 against Mycobacterium tuberculosis. Diagn Microbiol Infect Dis. 1991;14:465-471. DOI: 10.1016/0732-8893(91)90002-w
17. Sotgiu G., Centis R., D’Ambrosio L., Alffenaar J.W., Anger H.A., Caminero J.A., et al. Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and metaanalysis. Eur Respir J. 2012;40:1430-1442. DOI: 10.1183/09031936.00022912
18. Sotgiu G., Pontali E., Migliori G.B. Linezolid to treat MDR-/XDR-tuberculosis: available evidence and future scenarios. Eur Respir J. 2015;45:25-29. DOI: 10.1183/09031936.00145014
19. Sotgiu G., Tiberi S., D’Ambrosio L., Centis R., Alffenaar J.W., Caminero J.A. Faster for less: the new “shorter” regimen for multidrug-resistant tuberculosis. Eur Respir J. 2016;48:15031507. DOI: 10.1183/13993003.01249-2016
20. Van Deun A., Salim M.A., Das A.P., Bastian I., Portaels F. Results of a standardised regimen for multidrug-resistant tuberculosis in Bangladesh. Int J Tuberc Lung Dis. 2004;8:560-567. PMID: 15137531.
21. Tang S., Yao L., Hao X., Liu Y., Zeng L., Liu G., et al. Clofazimine for the treatment of multidrug-resistant tuberculosis: prospective, multicenter, randomized controlled study in China. Clin Infect Dis. 2015;60:13611367. DOI: 10.1093/cid/civ027
22. Tiberi S., D’Ambrosio L., De Lorenzo S., Viggiani P., Centis R., Sotgiu G., et al. Ertapenem in the treatment of multidrugresistant tuberculosis: first clinical experience. Eur Respir J. 2016;47:333-336. DOI: 10.1183/13993003.012782015
23. Diacon A.H., van der Merwe L., Barnard M., von GrooteBidlingmaier F., Lange C., García-Basteiro A.L., et al. b-Lactams against tuberculosis – new trick for an old dog? N Engl J Med. 2016;375:393-394. DOI: 10.1056/NEJMc1513236
24. Anglaret X., Chêne G., Attia A., Toure S., Lafont S., Combe P., et al. Early chemoprophylaxis with trimethoprimsulphamethoxazole for HIV-1-infected adults in Abidjan, Côte d’Ivoire: a randomised trial. Lancet. 1999;353:14631468. DOI: 10.1016/s0140-6736(98)07399-1
25. Walker A.S., Ford D., Gilks C.F., Munderi P., Ssali F., Reid A., et al. Daily co-trimoxazole prophylaxis in severely immunosuppressed HIV infected adults in Africa started on combination antiretroviral therapy: an observational analysis of the DART cohort. Lancet. 2010;375:1278-1286. DOI: 10.1016/S0140-6736(10)60057-8
26. Krieger D., Vesenbeckh S., Schönfeld N., Bettermann G., Bauer T.T., Russmann H., et al. Mefloquine as a potential drug against multidrug-resistant tuberculosis. Eur Respir J. 2015;46:1503-1505. DOI: 10.1183/13993003.003212015
27. Van der Paardt A.L., Akkerman O.W., Gualano G., Palmieri F., Davies Forsman L., Aleksa A., et al. Safety and tolerability of clarithromycin in the treatment of multidrugresistant tuberculosis. Eur Respir J. 2017;49:1601612. DOI: 10.1183/13993003.01612-2016
28. Working Group on New TB Drugs. Available at: www.newtbdrugs.org/pipeline/clinical. Accessed June 27, 2020.
29. NIH. U.S. National Library of Medicine. Available at: https://clinicaltrials.gov/ct2/show/NCT01225640. Accessed June 16, 2020.
30. World Health Organization. Technical report on critical concentrations for TB drug susceptibility testing of medicines used in the treatment of drug-resistant TB. 2018. Available at: www.who.int/tb/publications/2018/. Accessed January 2021.
31. Policy brief 29 World Health Organization 2018. Ensuring access to medicines: How to stimulate innovation to meet patients’ needs? Addressing policy failures in pharmaceuticals series editor. 2018. Available at: www.euro.who.int/data/assets/pdf_file/0009/379701/PB29. Accessed January 2021.
32. Sirturo (bedaquiline) [website]. Amsterdam, The Netherlands European Medicines Agency; 2020. Available at: www.ema.europa.eu/en/medicines/human/EPAR/sirturo. Accessed March 20, 2020.
33. Maryland, United States of America: US Food and Drug Administration. Sirturo (bedaquiline 100 mg tablets) For the treatment of adults (≥ 18 years) as part of combination therapy of pulmonary multi-drug resistant tuberculosis (MDRTB). November 28, 2012. Available at: www.natap.org/2013/newsUpdates/20121128-AIDAC-B1–01FDA_Backgrounder.pdf. Accessed March 20, 2020.
34. World Health Organization. The use of bedaquiline in the treatment of multidrug-resistant tuberculosis. Interim policy guidance (WHO/HTM/TB/2013.6). 2013. Available at: http://apps.who.int/iris/bitstream/handle/10665/84879/9789241505482_eng.pdf?sequence=1. Accessed January 2021.
35. World Health Organization. The use of delamanid in the treatment of multidrug-resistant tuberculosis. Interim policy guidance (WHO/HTM/TB/2014.23). 2014. Available at: http://apps.who.int/iris/bitstream/handle/10665/137334/WHO_HTM_TB_2014.23_eng.pdf?sequence=1. Accessed March 20, 2020.
36. European Medicines Agency. Deltyba. Available at: https://www.ema.europa.eu/en/medicines/human/EPAR/deltyba. Accessed March 20, 2020.
37. Sasaki H., Haraguchi Y., Itotani M., Kuroda H., Hashizume H., Tomishige T., et al. Synthesis and antituberculosis activity of a novel series of optically active 6-nitro-2,3-dihydroimidazo[2,1-b]oxazoles. J Med Chem. 2006;49:7854-7860. DOI: 10.1021/jm060957y
38. Tsubouchi H., Sasaki H., Ishikawa H., Matsumoto M. Discovery of delamanid for the treatment of multidrugresistant pulmonary tuberculosis. In: Successful Drug Discovery (eds J. Fischer and W.E. Childers); 2016. Charter 7. DOI: 10.1002/9783527800315.ch7
39. Liu Y., Matsumoto M., Ishida H., Ohguro K., Yoshitake M., Gupta R., et al. Delamanid: From discovery to its use for pulmonary multidrug-resistant tuberculosis (MDR-TB). Тuberculosis. 2018;111:20-30. DOI: 10.1016/j.tube.2018.04.008
40. Upton A.M., Cho S., Yang T.J., Kim A.Y., Wang Y., Lu Y., et al. In vitro and in vivo activities of the nitroimidazole TBA-354 against Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2015;59:136-144. DOI: 10.1128/AAC.03823-14
41. Matsumoto M., Hashizume H., Tomishige T., Kawasaki M., Tsubouchi H., Sasaki H., et al. OPC-67683, a nitro-dihydroimidazooxazole derivative with promising action against tuberculosis in vitro and in mice. PLoS Med. 2006;3:21312144. DOI: 10.1371/journal.pmed.0030466
42. Chen X., Hashizume H., Tomishige T., Nakamura I., Matsuba M., Fujiwara M., et al. Delamanid kills dormant mycobacteria in vitro and in a Guinea pig model of tuberculosis. Antimicrob Agents Chemother. 2017;61:111. DOI: 10.1128/AAC.02402-16
43. Doi N., Disratthakit A. Characteristic antimycobacterial spectra of the novel anti-TB drug candidates OPC-67683 and PA-824. Presented at Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), San Francisco, CA, 2016. Poster F1-1377a.
44. Shimokawa Y., Sasahara K., Koyama N., Kitano K., Shibata M., Yoda N., et al. Metabolic mechanism of delamanid, a new anti-tuberculosis drug, in human plasma. Drug Metab Dispos. 2015;43:1277-1283. DOI: 10.1124/dmd.115.064550
45. Gupta R., Geiter L.J., Hafkin J., Wells C.D. Delamanid and QT prolongation in the treatment of multidrug-resistant tuberculosis. Int J Tubercul Lung Dis. 2015;19:1261-1262. DOI: 10.5588/ijtld.15.0541
46. Fujiwara M., Kawasaki M., Hariguchi N., Liu Y., Matsumoto M. Mechanisms of resistance to delamanid, a drug for mycobacterium tuberculosis. Tuberculosis. 2018;108:186-194. DOI: 10.1016/j.tube.2017.12.006
47. Mallikaarjun S., Wells C., Petersen C., Paccaly A., Shoaf S.E., Patil S., et al. Delamanid coadministered with antiretroviral drugs or antituberculosis drugs shows no clinically relevant drug-drug interactions in healthy subjects. Antimicrob Agents Chemother. 2016;60:5976-5985. DOI: 10.1128/AAC.00509-16
48. World Health Organization. WHO treatment guidelines for drug-resistant tuberculosis, 2016 update (WHO/HTM/TB/2016.4). 2016. Available at: www.who.int/publications/i/item/9789241549639. Accessed January 30, 2021.
49. Sotgiu G., Tiberi S., D’Ambrosio L., Centis R., Zumla A., Migliori G.B. WHO recommendations on shorter treatment of multidrug-resistant tuberculosis. Lancet. 2016;387:24862487. DOI: 10.1016/S0140-6736(16)30729-2
50. World Health Organization. WHO consolidated guidelines on drug-resistant tuberculosis treatment, (WHO/CDS/TB/2019.7). 2019. Available at: https://apps.who.int/iris/bitstream/handle/10665/311389/9789241550529eng.pdf?ua=1. Accessed January 30, 2021.
51. World Health Organization. WHO Consolidated Guidelines on Tuberculosis. Module 4: treatment – drug-resistant tuberculosis treatment. 2020. Available at: https://apps.who.int/iris/bitstream/handle/10665/329298/9789289054461-rus.pdf?sequence=1&isAllowed=y. Accessed January 30, 2021. Russian.
52. Borisov S.E., Dheda K., Enwerem M., Romero Leyet R., D’Ambrosio L., Centis R., et al. Effectiveness and safety of bedaquiline-containing regimens in the treatment of MDR- and XDR-TB: a multicentre study. Eur Respir J. 2017;49(5):1700387. DOI: 10.1183/13993003.00387-2017
53. Hafkin J., Hittel N., Martin A., Gupta R. Early outcomes in MDR-TB and XDR-TB patients treated with delamanid under compassionate use. Eur Respir J. 2017;50:1700311. DOI: 10.1183/13993003.00311-2017
54. Von Groote-Bidlingmaier F., Patientia R., Sanchez E., Balanag V. Jr, Ticona E., Seguraet P., et al. Efficacy and safety of delamanid in combination with an optimised background regimen for treatment of multidrug-resistant tuberculosis: a multicentre, randomised, double-blind, placebo-controlled, parallel group phase 3 trial. Lancet. Respir Med. 2019;7(3):249-259. DOI: 10.1016/s22132600(18)30426-0
55. Lorsanov S.M., Khaydarkhanova Z.B., Khunkarsultanov S.B. The experience of using delamanid in the Chechen Republic. Tuberkuljoz i bolezni ljogkih. 2019;97(12):6263. Russian. DOI: 10.21292/2075-12302019-97-12-62-63
56. World Health Organization. Global tuberculosis report 2016. Available at: https://apps.who.int/iris/handle/10665/250441. Accessed January 30, 2021.
57. Sotgiu G., Tiberi S., D’Ambrosio L., Centis R., Alffenaar J.W., Caminero J.A. Faster for less: the new ‘shorter’ regimen for multidrug-resistant tuberculosis. Eur Respir J. 2016;48:15031507. DOI: 10.1183/13993003.01249-2016
58. Van Deun A., Maug A., Salim A., Das P., Sarker M., Daru P., et al. Short, highly effective, and inexpensive standardised, treatment of multidrug-resistant tuberculosis. Am J Respir Crit Care Med. 2010;182:684-692. DOI: 10.1164/rccm.201001-0077OC
59. Aung K.J., Van Deun A., Declercq E., Sarker M.R., Das P.K., Hossain M.A., et al. Successful ‘9-month Bangladesh regimen’ for multidrugresistant tuberculosis among over 500 consecutive patients. Int J Tuberc Lung Dis. 2014:18:11801187. DOI: 10.5588/ijtld.14.0100
60. Ahmad Khan F., Salim M.A.H., du Cros P., Casas E.C., Khamraev A., Sikhondze W., et al. Effectiveness and safety of standardised shorter regimens for multidrug-resistant tuberculosis: individual patient data and aggregate data meta-analyses. Eur Respir J. 2017;50:1700061. DOI: 10.1183/13993003.00061-2017
61. Combs D.L., O’Brien R.J., Geiter L.J. USPHS Tuberculosis Short-Course Chemotherapy Trial: effectiveness, toxicity, and acceptability. The report of final results. Ann Intern Med. 1990;112(6):397-406. DOI: 10.7326/00034819-76-3-112-6-397
62. World Health Organization. Guidelines for treatment of drug-susceptible tuberculosis and patient care 2017, update, (WHO/HTM/TB/2017.05). 2017. Available at: http://apps.who.int/iris/bitstream/handle/10665/255052/9789241550000-eng.pdf?sequence=1. Accessed January 30, 2021.
63. World Health Organization. WHO consolidated guidelines on tuberculosis. Module 4: treatment – drug-resistant tuberculosis treatment. 2020. Available at: https://apps.who.int/iris/bitstream/handle/10665/332397/9789240007048eng.pdf?sequence=1&isAllowed=y. Accessed January 30, 2021.
64. The Evaluation of a Standard Treatment Regimen of Antituberculosis Drugs for Patients With MDR-TB (STREAM). Available at: https://clinicaltrials.gov/ct2/show/NCT02409290. Accessed January 30, 2021.
65. Moodley R., Godec T.R., STREAM Trial Team. Shortcourse treatment for multidrug-resistant tuberculosis: the STREAM trials. Eur Respir Rev. 2016;25(139):29-35. DOI: 10.1183/16000617.0080-2015
66. Conradie F., Diacon A.H., Ngubane N. Treatment of highly drug-resistant pulmonary tuberculosis. N Engl J Med. 2020;382(10):893-902. DOI: 10.1056/NEJMoa1901814
67. Mok J., Kang H., Hwang S.H., Park J.S., Kang B., Lee T., et al. Interim outcomes of delamanid for the treatment of MDR- and XDR-TB in South Korea. J Antimicrob Chemother. 2018;73(2):503-508. DOI: 10.1093/jac/dkx373
68. Wirth D., Dass R., Hettle R. Cost-effectiveness of adding novel or group 5 interventions to a background regimen for the treatment of multidrug-resistant tuberculosis in Germany. BMC Health Serv Res. 2017;17(1):182. DOI: 10.1186/s12913-017-2118-2
69. Colvin C., De Silva G., Garfin C., Alva S., Cloutier S., Gavoiola D., et al. Quality of TB services assessment: The unique contribution of patient and provider perspectives in identifying and addressing gaps in the quality of TB services. J Clin Tuberc Other Mycobact Dis. 2019;:100117. DOI: 10.1016/J.JCTUBE.2019.100117
70. Khan U., Huerga H., Khan A.J., Mitnick C.D., Hewison C., Varaine F., et al. The endTB observational study protocol: treatment of MDR-TB with bedaquiline or delamanid containing regimens. BMC Infect Dis. 2019;19(733). DOI: 10.1186/s12879-019-4378-4
71. World Health Organization. WHO best-practice statement on the off-label use of bedaquiline and delamanid for the treatment of multidrug-resistant tuberculosis (WHO/HTM/TB/2017.20). 2017. Available at: https://apps.who.int/iris/bitstream/handle/10665/258941/WHO-HTM-TB2017.20-eng.pdf?sequence=1. Accessed January 30, 2021.
72. Evaluating Newly Approved Drugs in Combination Regimens for Multidrug-Resistant TB With Fluoroquinolone Resistance (endTB-Q) (endTB-Q). ClinicalTrials.gov Identifier: NCT03896685. Available at: https://clinicaltrials.gov/ct2/show/NCT03896685. Accessed January 30, 2021.
73. Skryagina A.M., Solodovnikova V.V., Klimuk D.A., Vetushko D.A., Yakubenya O.N, Zhurkin D.A. Preliminary treatment results of patients with XDR- and preXDR-TB using new anti-tuberculosis drugs. Achievements of medical science in Belarus. 2019. Heading 76.29.53. Russian.
74. World Health Organization. The use of delamanid in the treatment of multidrug-resistant tuberculosis in children and adolescents: Interim policy guidance. 2016. Available at: https://apps.who.int/iris/bitstream/handle/10665/250614/9789241549899-eng.pdf?sequence=1. Accessed January 30, 2021.
75. Call to action: Accelerate access to DR-TB drugs. Available at: http://www.tbonline.info/posts/2015/3/17/callaction-accelerate-access-dr-tb-drugs-1. Accessed January 30, 2021.
76. DR-TB Scale-up Treatment Action Team (STAT). Available at: http://drtb-stat.org/wp-content/uploads/2015/10/TermsofReference.pdf. Accessed January 30, 2021.
77. Cumulative programmatic use of bedaquiline and delamanid. Available at: http://drtb-stat.org/wp-content/uploads/2020/04/DR-TB-STAT-March-2020-GlobalSummary.pdf. Accessed January 30, 2021.
78. Wolfson L.J., Walker A., Hettle R., Lu X., Kambili C., Murungi A., Knerer G. Cost-effectiveness of adding bedaquiline to drug regimens for the treatment of multidrug-resistant tuberculosis in the UK. PLoS One. 2015;10(3):e0120763. DOI: 10.1371/journal.pone.0120763
79. Veziris N., Bernard C., Guglielmetti L., Le Du D., MarigotOuttandy D., Jaspard M., et al. Rapid emergence of Mycobacterium tuberculosis bedaquiline resistance: lessons not to repeat past errors. Eur Respir J. 2017;49(3):1601719. DOI: 10.1183 / 13993003.01719-2016
80. World Health Organization. Guidelines for establishing DOTS-Plus pilot projects for the management of multidrug-resistant tuberculosis (MDR-TB) (WHO/CDS/TB/2000.279). 2000. Available at: https://apps.who.int/iris/bitstream/handle/10665/66368/WHO_CDS_TB_2000.279.pdf?sequence=1. Accessed January 30, 2021.
81. Conradie F., Diacon A.H., Ngubane N. Treatment of highly drug-resistant pulmonary tuberculosis. N Engl J Med. 2020;382(10):893-902. DOI: 10.1056/NEJMoa1901814
82. World Health Organization. Rapid communication: key changes to treatment of multidrug-and rifampicinresistant tuberculosis (WHO/CDS/TB/2018.18). 2018. Available at: www.who.int/tb/publications/2018/rapid_communications_MDR/en/. Accessed October 12, 2020.
83. Migliori G.B., Global Tuberculosis Network (GTN). Evolution of programmatic definitions used in tuberculosis prevention and care. Clin Infect Dis. 2019;68(10):17871789. DOI: 10.1093/cid/ciy990
84. Centis R., Sotgiu G., Migliori G.B. Delamanid: does it have a role in tuberculosis treatment? Lancet Respir Med. 2019;7(3):193-195. DOI: 10.1016/s22132600(18)30455-7
85. Clinical guidelines for the diagnosis and treatment of tuberculosis and its drug-resistant forms. Order of the ministry of health of the Republic of Belarus. Available at: www.rnpcpf.by/ru/organizacionno-metodicheskayarabota/normativno-pravovye-akty-po-slujbe.html?start=10. Russian.
86. Tuberculosis in adults. Clinical guidelines. 2020. Available at: https://legalacts.ru/doc/klinicheskie-rekomendatsiituberkulez-u-vzroslykh-utv-minzdravom-rossii/. Accessed January 30, 2021. Russian.
87. The list of vital and essential medicines for medical use in the Russian Federation for 2020. Approved by the order of the Government of the Russian Federation October 12, 2019 No 2406-p. Available at: http://government.ru/docs/38100. Accessed January 30, 2021. Russian.
88. World Health Organization. Global tuberculosis report 2019 (WHO/CDS/TB/2019.15). 2020 Available at: https://www.who.int/tb/publications/global_report/en/. Accessed May 29, 2020.
89. Hewison C., Ferlazzo G., Avaliani Z., Hayrapetyan A., Jonckheere S., Khaidarkhanova Z., et al. Six-month response to delamanid treatment in MDR TB patients. Emerg Infect Dis. 2017;23(10):1746-1748. DOI: 10.3201/eid2310.170468
90. Kuksa L., Barkane L., Hittel N., Gupta R. Final treatment outcomes of multidrug- and extensively drug-resistant tuberculosis patients in Latvia receiving delamanidcontaining regimens. Eur Respir J. 2017;50:2-5. DOI: 10.1183/13993003.01105-2017

Views

0 Abstract

0 PDF

0 Crossref citations

New regimens and new medications in the treatment of tuberculosis: keeping step?

Abstract

Views

Shared

Cited by Crossref